Switzerland

Switzerland

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.79 (0.65 - 0.91) 2019 Modelled IHME
0.78 (0.66 - 0.91) 2018 Modelled IHME
0.78 (0.66 - 0.92) 2017 Modelled IHME
0.79 (0.68 - 0.92) 2016 Modelled IHME
0.81 (0.68 - 0.93) 2015 Modelled IHME
0.81 (0.69 - 0.92) 2014 Modelled IHME
0.81 (0.69 - 0.92) 2013 Modelled IHME
0.81 (0.69 - 0.92) 2012 Modelled IHME
0.81 (0.68 - 0.93) 2011 Modelled IHME
0.81 (0.68 - 0.93) 2010 Modelled IHME
0.81 (0.68 - 0.93) 2009 Modelled IHME
0.81 (0.68 - 0.92) 2008 Modelled IHME
0.81 (0.68 - 0.93) 2007 Modelled IHME
0.82 (0.68 - 0.94) 2006 Modelled IHME
0.82 (0.68 - 0.95) 2005 Modelled IHME
0.82 (0.68 - 0.95) 2004 Modelled IHME
0.82 (0.69 - 0.95) 2003 Modelled IHME
0.83 (0.69 - 0.95) 2002 Modelled IHME
0.83 (0.70 - 0.96) 2001 Modelled IHME
0.83 (0.70 - 0.96) 2000 Modelled IHME
0.83 (0.70 - 0.96) 1999 Modelled IHME
0.83 (0.71 - 0.96) 1998 Modelled IHME
0.83 (0.71 - 0.96) 1997 Modelled IHME
0.83 (0.71 - 0.96) 1996 Modelled IHME
0.83 (0.70 - 0.97) 1995 Modelled IHME
0.83 (0.71 - 0.97) 1994 Modelled IHME
0.83 (0.71 - 0.97) 1993 Modelled IHME
0.84 (0.71 - 0.97) 1992 Modelled IHME
0.84 (0.71 - 0.97) 1991 Modelled IHME
0.84 (0.71 - 0.98) 1990 Modelled IHME
0.17 (0.09 - 0.31) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.15 (0.10 - 0.20) 2019 Modelled IHME
0.16 (0.11 - 0.22) 2018 Modelled IHME
0.18 (0.12 - 0.25) 2017 Modelled IHME
0.22 (0.15 - 0.31) 2016 Modelled IHME
0.27 (0.17 - 0.37) 2015 Modelled IHME
0.29 (0.19 - 0.39) 2014 Modelled IHME
0.3 (0.20 - 0.40) 2013 Modelled IHME
0.31 (0.20 - 0.42) 2012 Modelled IHME
0.32 (0.21 - 0.43) 2011 Modelled IHME
0.33 (0.22 - 0.45) 2010 Modelled IHME
0.33 (0.22 - 0.46) 2009 Modelled IHME
0.34 (0.22 - 0.48) 2008 Modelled IHME
0.34 (0.23 - 0.49) 2007 Modelled IHME
0.34 (0.23 - 0.50) 2006 Modelled IHME
0.35 (0.23 - 0.51) 2005 Modelled IHME
0.35 (0.23 - 0.51) 2004 Modelled IHME
0.35 (0.23 - 0.51) 2003 Modelled IHME
0.35 (0.23 - 0.51) 2002 Modelled IHME
0.35 (0.24 - 0.51) 2001 Modelled IHME
0.35 (0.24 - 0.50) 2000 Modelled IHME
0.35 (0.24 - 0.51) 1999 Modelled IHME
0.35 (0.24 - 0.51) 1998 Modelled IHME
0.35 (0.25 - 0.50) 1997 Modelled IHME
0.35 (0.25 - 0.49) 1996 Modelled IHME
0.35 (0.25 - 0.49) 1995 Modelled IHME
0.35 (0.25 - 0.49) 1994 Modelled IHME
0.35 (0.25 - 0.48) 1993 Modelled IHME
0.36 (0.24 - 0.48) 1992 Modelled IHME
0.36 (0.24 - 0.48) 1991 Modelled IHME
0.36 (0.24 - 0.49) 1990 Modelled IHME
0.17 (0.09 - 0.31) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (8 - 18) 2019 Modelled IHME
12 (8 - 18) 2018 Modelled IHME
12 (8 - 18) 2017 Modelled IHME
12 (8 - 18) 2016 Modelled IHME
12 (8 - 18) 2015 Modelled IHME
12 (8 - 18) 2014 Modelled IHME
13 (9 - 18) 2013 Modelled IHME
13 (9 - 18) 2012 Modelled IHME
13 (9 - 18) 2011 Modelled IHME
13 (9 - 19) 2010 Modelled IHME
13 (9 - 19) 2009 Modelled IHME
13 (9 - 19) 2008 Modelled IHME
13 (9 - 18) 2007 Modelled IHME
13 (9 - 18) 2006 Modelled IHME
13 (9 - 18) 2005 Modelled IHME
13 (9 - 18) 2004 Modelled IHME
13 (9 - 18) 2003 Modelled IHME
13 (9 - 18) 2002 Modelled IHME
13 (9 - 19) 2001 Modelled IHME
13 (9 - 19) 2000 Modelled IHME
13 (9 - 18) 1999 Modelled IHME
13 (9 - 18) 1998 Modelled IHME
13 (9 - 18) 1997 Modelled IHME
13 (9 - 18) 1996 Modelled IHME
13 (9 - 18) 1995 Modelled IHME
13 (9 - 18) 1994 Modelled IHME
13 (9 - 18) 1993 Modelled IHME
13 (9 - 18) 1992 Modelled IHME
13 (9 - 18) 1991 Modelled IHME
12 (8 - 18) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
72 2018 Survey/reported WHO/UNICEF

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
187 (156 - 234) 2011 Survey/reported Arnaud S, Jeannin A, Dubois-Arber F., 2011
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2018
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.87 (0.71 - 1.06) 2019 Modelled IHME
0.87 (0.71 - 1.05) 2018 Modelled IHME
0.86 (0.71 - 1.05) 2017 Modelled IHME
0.85 (0.69 - 1.02) 2016 Modelled IHME
0.83 (0.67 - 1.01) 2015 Modelled IHME
0.83 (0.67 - 1.01) 2014 Modelled IHME
0.83 (0.68 - 1) 2013 Modelled IHME
0.83 (0.68 - 1) 2012 Modelled IHME
0.83 (0.67 - 1.02) 2011 Modelled IHME
0.83 (0.67 - 1.02) 2010 Modelled IHME
0.83 (0.67 - 1.01) 2009 Modelled IHME
0.82 (0.67 - 0.99) 2008 Modelled IHME
0.81 (0.66 - 0.98) 2007 Modelled IHME
0.8 (0.65 - 0.96) 2006 Modelled IHME
0.79 (0.64 - 0.96) 2005 Modelled IHME
0.79 (0.64 - 0.95) 2004 Modelled IHME
0.78 (0.63 - 0.95) 2003 Modelled IHME
0.78 (0.63 - 0.95) 2002 Modelled IHME
0.77 (0.63 - 0.95) 2001 Modelled IHME
0.76 (0.62 - 0.95) 2000 Modelled IHME
0.76 (0.61 - 0.94) 1999 Modelled IHME
0.75 (0.61 - 0.92) 1998 Modelled IHME
0.74 (0.60 - 0.91) 1997 Modelled IHME
0.73 (0.59 - 0.89) 1996 Modelled IHME
0.72 (0.58 - 0.88) 1995 Modelled IHME
0.71 (0.58 - 0.87) 1994 Modelled IHME
0.71 (0.57 - 0.86) 1993 Modelled IHME
0.7 (0.57 - 0.85) 1992 Modelled IHME
0.69 (0.57 - 0.84) 1991 Modelled IHME
0.69 (0.56 - 0.84) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.5 (0.70 - 1.80) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
74.6 (69.30 - 79.40) 2014 Survey/reported Moriggia A et al, 2016

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
38 (28 - 48) 2019 Modelled IHME
38 (28 - 47) 2018 Modelled IHME
38 (28 - 47) 2017 Modelled IHME
38 (28 - 47) 2016 Modelled IHME
38 (28 - 48) 2015 Modelled IHME
38 (28 - 48) 2014 Modelled IHME
38 (28 - 47) 2013 Modelled IHME
37 (28 - 47) 2012 Modelled IHME
37 (28 - 47) 2011 Modelled IHME
37 (27 - 47) 2010 Modelled IHME
37 (27 - 46) 2009 Modelled IHME
37 (27 - 46) 2008 Modelled IHME
37 (27 - 46) 2007 Modelled IHME
37 (27 - 46) 2006 Modelled IHME
37 (27 - 46) 2005 Modelled IHME
37 (27 - 46) 2004 Modelled IHME
36 (27 - 46) 2003 Modelled IHME
36 (27 - 46) 2002 Modelled IHME
36 (26 - 45) 2001 Modelled IHME
35 (26 - 45) 2000 Modelled IHME
36 (26 - 45) 1999 Modelled IHME
35 (26 - 45) 1998 Modelled IHME
35 (26 - 45) 1997 Modelled IHME
35 (26 - 45) 1996 Modelled IHME
35 (26 - 44) 1995 Modelled IHME
35 (26 - 44) 1994 Modelled IHME
35 (26 - 44) 1993 Modelled IHME
35 (25 - 44) 1992 Modelled IHME
34 (25 - 44) 1991 Modelled IHME
35 (25 - 44) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (156 - 234) 2011 Survey/reported Arnaud S, Jeannin A, Dubois-Arber F., 2011
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
Pregnant women
HepB birth dose policy
Yes
Year of birth dose introduction
2018
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
Risk-based
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
0.79 (%)
2019
(0.65 - 0.91(%))
IHME
HCV (RNA/cAg+)
0.87 (%)
2019
(0.71 - 1.06(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
212
2019
(163 - 273)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
461
2019
(363 - 565)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.15 (%)
2019, latest modelled
(0.10 - 0.20(%))
IHME

Prevalence PWID

HCV
74.60 (%)
2014, survey/surveillance
(69.30 - 79.40(%))
Moriggia A et al, 2016

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
187
2011
(156 - 234)
Arnaud S, Jeannin A, Dubois-Arber F., 2011
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources